Your browser is no longer supported. Please, upgrade your browser.
HomeNewsScreenerMapsGroupsPortfolioInsiderFuturesForexCryptoBacktestsElite Help
publish chart | save to portfolio | create alert Type: candle | line | advanced | interactive | perf    Timeframe: intraday | daily | weekly | monthly  Settings
VNDA Vanda Pharmaceuticals Inc. daily Stock Chart
VNDA [NASD]
Vanda Pharmaceuticals Inc.
Healthcare | Biotechnology | USA
financial highlights | statements
Index- P/E88.33 EPS (ttm)0.24 Insider Own3.20% Shs Outstand52.56M Perf Week11.40%
Market Cap1.11B Forward P/E56.90 EPS next Y0.37 Insider Trans-1.67% Shs Float51.20M Perf Month-30.03%
Income13.00M PEG- EPS next Q0.01 Inst Own- Short Float8.46% Perf Quarter-6.47%
Sales184.40M P/S6.02 EPS this Y16.00% Inst Trans1.07% Short Ratio4.72 Perf Half Y-3.17%
Book/sh4.99 P/B4.23 EPS next Y32.97% ROA4.60% Target Price41.67 Perf Year33.19%
Cash/sh4.58 P/C4.61 EPS next 5Y- ROE5.90% 52W Range13.88 - 33.44 Perf YTD-19.21%
Dividend- P/FCF62.69 EPS past 5Y19.30% ROI-13.00% 52W High-36.87% Beta0.66
Dividend %- Quick Ratio6.00 Sales past 5Y38.20% Gross Margin89.40% 52W Low52.14% ATR1.47
Employees273 Current Ratio6.00 Sales Q/Q18.90% Oper. Margin5.70% RSI (14)38.20 Volatility8.61% 5.88%
OptionableYes Debt/Eq0.00 EPS Q/Q229.30% Profit Margin7.10% Rel Volume1.74 Prev Close20.12
ShortableYes LT Debt/Eq0.00 EarningsFeb 13 AMC Payout0.00% Avg Volume917.02K Price21.11
Recom1.70 SMA20-15.84% SMA50-19.86% SMA200-2.52% Volume1,598,636 Change4.92%
Dec-11-18Downgrade Oppenheimer Outperform → Perform
Dec-04-18Upgrade Cantor Fitzgerald Neutral → Overweight
Dec-04-18Reiterated Jefferies Buy $30 → $40
Nov-08-18Resumed Jefferies Buy
Sep-21-18Resumed Oppenheimer Outperform
May-23-18Initiated Citigroup Buy $26
Jan-19-18Initiated Seaport Global Securities Buy $20
Sep-14-17Reiterated Piper Jaffray Overweight $23 → $26
Jun-27-17Resumed Piper Jaffray Overweight $23
May-26-17Initiated H.C. Wainwright Buy $18
Apr-12-17Initiated Oppenheimer Outperform $21
Nov-09-16Initiated Aegis Capital Buy $24
Oct-06-16Resumed Jefferies Buy
Jan-09-15Initiated Canaccord Genuity Buy $22
Mar-10-10Initiated Hapoalim Outperform $23
Feb-17-10Reiterated Jefferies & Co Buy $22 → $20
Dec-09-09Initiated Jefferies & Co Buy $22
Jul-29-08Downgrade JP Morgan Overweight → Neutral
Jul-29-08Downgrade Banc of America Sec Buy → Neutral
Jul-28-08Downgrade Caris & Company Buy → Above Average $22 → $3
Feb-15-19 06:31AM  3 Top Growth Stocks to Buy Right Now Motley Fool
Feb-14-19 03:41PM  Here's Why Vanda Pharmaceuticals Gained as Much as 11.1% Today Motley Fool +9.23%
03:00PM  ONGOING INVESTIGATION: The Schall Law Firm Announces it is Investigating Claims Against Vanda Pharmaceuticals Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm GlobeNewswire
03:00PM  VANDA INVESTOR ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $50,000 Investing In Vanda Pharmaceuticals Inc. To Contact The Firm ACCESSWIRE
11:00AM  Glancy Prongay & Murray LLP Announces Investigation on Behalf of Vanda Pharmaceuticals Inc. Investors Business Wire
07:50AM  The Daily Biotech Pulse: Vanda Q4 Results, Inovio Debt Offering, Caladrius Diabetes Drug Flunks Mid-Stage Trial Benzinga
12:21AM  Vanda Pharmaceuticals Inc (VNDA) Q4 2018 Earnings Conference Call Transcript Motley Fool
Feb-13-19 05:25PM  Vanda Pharmaceuticals (VNDA) Tops Q4 Earnings and Revenue Estimates Zacks
05:10PM  INVESTOR ALERT: Law Offices of Howard G. Smith Announces Investigation on Behalf of Vanda Pharmaceuticals Inc. Investors (VNDA) Business Wire
04:28PM  Vanda: 4Q Earnings Snapshot Associated Press
04:01PM  Vanda Pharmaceuticals Reports Fourth Quarter 2018 and Full Year 2018 Financial Results PR Newswire
03:16PM  INVESTIGATION REMINDER: The Schall Law Firm Announces it is Investigating Claims Against Vanda Pharmaceuticals Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm Business Wire
02:30PM  Vanda Pharmaceuticals Inc. to Host Earnings Call ACCESSWIRE
01:00PM  VANDA INVESTOR ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $50,000 Investing In Vanda Pharmaceuticals Inc. To Contact The Firm PR Newswire
07:49AM  The Daily Biotech Pulse: Exelixis Q4 Results, FDA Panel Greenlights J&J's Depression Drug, MacroGenics Prices Offering Benzinga
Feb-12-19 04:22PM  INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Vanda Pharmaceuticals Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm Business Wire
03:11PM  D.C. drug company sues FDA over clinical trials American City Business Journals
10:40AM  SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Announces Investigation of Vanda Pharmaceuticals Inc. (VNDA) GlobeNewswire
08:32AM  Wolf Popper LLP Announces Investigation on Behalf of Investors in Vanda Pharmaceuticals Inc. PR Newswire
Feb-11-19 07:00PM  INVESTOR ALERT: Kirby McInerney LLP Announces an Investigation of Shareholder Claims Against Vanda Pharmaceuticals Inc. Business Wire -5.01%
05:01PM  INVESTOR ALERT: Law Offices of Howard G. Smith Announces Investigation on Behalf of Vanda Pharmaceuticals Inc. Investors (VNDA) Business Wire
03:12PM  Bragar Eagel & Squire, P.C. is Investigating Vanda Pharmaceuticals Inc. (VNDA) on Behalf of Stockholders and Encourages VNDA Investors to Contact the Firm GlobeNewswire
11:38AM  EQUITY ALERT: Rosen Law Firm Announces Investigation of Securities Claims Against Vanda Pharmaceuticals Inc. Business Wire
11:07AM  Pharma Stock Eyes 11th Straight Loss After Short Report Schaeffer's Investment Research
10:49AM  Vanda Pharmaceuticals Inc. Investigated by Block & Leviton LLP For Violations of Federal Securities Laws GlobeNewswire
Feb-06-19 12:21PM  Here's Why Vanda Pharmaceuticals Is Sinking Today Motley Fool -19.95%
Feb-05-19 05:05PM  Vanda Pharmaceuticals Takes a Stand Against Unnecessary Animal Research PR Newswire
Jan-29-19 07:40AM  New Research: Key Drivers of Growth for McCormick & Company, Darden Restaurants, Vanda Pharmaceuticals, SunPower, Pretium Resources, and America's Car-Mart Factors of Influence, Major Initiatives and Sustained Production GlobeNewswire
Jan-28-19 11:28AM  Should You Worry About Vanda Pharmaceuticals Inc.s (NASDAQ:VNDA) CEO Salary Level? Simply Wall St.
Jan-25-19 09:30AM  Vanda Pharmaceuticals to Announce Fourth Quarter and Full Year 2018 Financial Results on February 13, 2019 PR Newswire
Jan-17-19 10:18AM  Amgen's Postmenopausal Osteoporosis Drug Gets FDA Panel Nod Zacks
08:23AM  Zacks.com featured highlights include: Inseego, Meet, Vanda, Crocs and Bluerock Residential Zacks
Jan-16-19 06:59AM  5 Stocks With Recent Price Strength Despite Volatile Market Zacks
Jan-14-19 09:46AM  ASLAN's Varlitinib Fails to Meet Endpoint in Phase II Study Zacks
Jan-10-19 10:00AM  Acorda (ACOR) Plans to Launch Inbrija in Q1: What to Expect Zacks
Jan-09-19 09:50AM  Amgen's Osteoporosis Candidate Evenity Gets Approval in Japan Zacks
Jan-08-19 05:20PM  Emergent (EBS) Up on '19 View, Posts Preliminary '18 Results Zacks
Jan-07-19 10:09AM  Emergent (EBS) CEO Abdun Nabi to Retire, Kramer to Succeed Zacks
Jan-04-19 12:02PM  Bull or Bear: Your Investment Strategy for 2019 Zacks +6.69%
10:01AM  Vertex Joins Forces With Arbor to Build Gene-Editing Therapies Zacks
Dec-31-18 08:10AM  Emergent (EBS) Files Application for Emergency Use of NuThrax Zacks
07:51AM  4 of the Fastest Growing Biotech Stocks in 2019 Motley Fool
Dec-24-18 08:39AM  Ring in 2019 With These 7 Solid Growth Stocks in Your Kitty Zacks
Dec-21-18 03:57PM  These 2 Biotech Stocks Snub The Stock Market Correction Investor's Business Daily
Dec-20-18 07:00AM  FDA Accepts HETLIOZ® (tasimelteon) Supplemental New Drug Application for Review in the Treatment of Jet Lag Disorder PR Newswire
Dec-16-18 09:45AM  Vanda Pharmaceuticals Inc. (VNDA): Hedge Fund Sentiment Unchanged Insider Monkey
Dec-14-18 07:11AM  The Zacks Analyst Blog Highlights: Vanda Pharmaceuticals, Penumbra, G-III Apparel and General Finance Zacks
06:59AM  How Does Investing In Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) Impact The Volatility Of Your Portfolio? Simply Wall St.
06:33AM  The Zacks Analyst Blog Highlights: Vanda Pharmaceuticals, Penumbra, G-III Apparel and General Finance Zacks
Dec-13-18 09:21AM  The Zacks Analyst Blog Highlights: Vanda Pharmaceuticals, Penumbra, G-III Apparel and General Finance Zacks
Dec-12-18 09:02AM  4 Stocks That Had Massive Earnings Surprises in 2018 Zacks
Dec-10-18 07:00AM  Vanda Announces Positive Pivotal Study Results for HETLIOZ® (tasimelteon) in Patients with Smith-Magenis Syndrome PR Newswire
Dec-05-18 09:49AM  Inovio (INO) to Receive Milestone Payment From AstraZeneca Zacks
Dec-04-18 04:34PM  Amgen's BiTE Immunotherapies Show Promise in Early Studies Zacks -8.04%
09:30AM  Company News For Dec 4, 2018 Zacks
07:59AM  The Daily Biotech Pulse: ASH Presentations Take The Spotlight, Eiger Gets A New CFO Benzinga
Dec-03-18 09:41AM  FDA Committee to Review Amgen's (AMGN) Osteoporosis Candidate Zacks +25.68%
06:00AM  Vanda Announces Positive Phase II Study Results for Tradipitant in Patients with Gastroparesis PR Newswire
Nov-29-18 08:05AM  Zacks.com highlights: Vericel, Mitek, Vanda Pharmaceuticals, Mosaic and Spirit Airlines Zacks
Nov-28-18 08:18AM  5 Stocks With Recent Price Strength to Strengthen Portfolio Zacks
Nov-20-18 03:52PM  Edited Transcript of VNDA earnings conference call or presentation 7-Nov-18 9:30pm GMT Thomson Reuters StreetEvents
Nov-16-18 10:20AM  Earnings Estimates Moving Higher for Vanda (VNDA): Time to Buy? Zacks
Nov-08-18 05:35PM  Vanda Pharmaceuticals Announces Participation at November 2018 Investor Conferences PR Newswire +14.72%
04:16PM  This Biotech Stock Briefly Edged Into Buy Zone On Earnings Crush Investor's Business Daily
Nov-07-18 06:25PM  Vanda Pharmaceuticals (VNDA) Surpasses Q3 Earnings and Revenue Estimates Zacks
05:22PM  Vanda: 3Q Earnings Snapshot Associated Press
04:01PM  Vanda Pharmaceuticals Reports Third Quarter 2018 Financial Results PR Newswire
Nov-02-18 02:06PM  The FDA is cracking down on a local drugmaker. The company isn't completely sure why. American City Business Journals
Nov-01-18 01:30PM  A Look At The Intrinsic Value Of Vanda Pharmaceuticals Inc (NASDAQ:VNDA) Simply Wall St. +6.91%
09:40AM  Vanda Receives FDA Letter Regarding Corporate Webpage PR Newswire
Oct-31-18 10:32AM  Vanda Pharmaceuticals (VNDA) Earnings Expected to Grow: What to Know Ahead of Next Week's Release Zacks
Oct-24-18 07:30AM  Consolidated Research: 2018 Summary Expectations for Airgain, Vanda Pharmaceuticals, Westlake Chemical, TransEnterix, Versum Materials, and Triumph Group Fundamental Analysis, Key Performance Indications GlobeNewswire -7.54%
Oct-23-18 04:41PM  This IBD Stock Of The Day Is Heading For Fourth Quarter Of Profitability Investor's Business Daily
Oct-22-18 04:30PM  Vanda Pharmaceuticals to Announce Third Quarter 2018 Financial Results on November 7, 2018 PR Newswire
Sep-27-18 08:31AM  Vanda Pharmaceuticals (VNDA) Catches Eye: Stock Jumps 8.7% Zacks
Sep-26-18 04:30PM  Vanda Pharmaceuticals Announces Participation at Oppenheimer and Cantor Fitzgerald Fall 2018 Investor Conferences PR Newswire +8.72%
04:19PM  Here's Why The Stock Market Sold Off After The Fed Meeting Investor's Business Daily
02:41PM  Why Vanda Pharmaceuticals' Shares Are Soaring 10% Today Motley Fool
08:25AM  The Daily Biotech Pulse: Verastem's Chinese Duvelisib Licensing Deal, Aldeyra's Positive Dry Eye Disease Drug Trial Benzinga
Sep-25-18 06:26PM  Rollins Set to Join S&P 500; Inogen to Join S&P MidCap 400; Vanda Pharmaceuticals and Garrett Motion to Join S&P SmallCap 600 PR Newswire
Sep-20-18 05:05PM  Vanda Announces Listing of a New HETLIOZ® Patent in the FDA Orange Book PR Newswire
Sep-17-18 12:00PM  Vanda Pharmaceuticals Inc (NASDAQ:VNDA): Commentary On Fundamentals Simply Wall St.
Sep-12-18 07:00PM  HETLIOZ® (Tasimelteon) Driving Study Demonstrates No Impairment in Next Morning Performance PR Newswire
Sep-04-18 04:35PM  Vanda Pharmaceuticals Announces Participation at September 2018 Investor Conferences PR Newswire
Aug-14-18 04:45PM  Vanda Wins Denial of Petition For Rehearing on Fanapt® PR Newswire
Aug-13-18 04:01PM  Vanda Pharmaceuticals Announces the Appointment of General Counsel PR Newswire
09:40AM  Edited Transcript of VNDA earnings conference call or presentation 1-Aug-18 8:30pm GMT Thomson Reuters StreetEvents
Aug-06-18 09:11AM  Zacks.com highlights: G-III Apparel Group, Rocky Brands, Vail Resorts, Vanda Pharmaceuticals and IntriCon Zacks
Aug-03-18 05:38PM  Ultragenyx (RARE) Posts Narrower-than-Expected Loss in Q2 Zacks
09:51AM  5 Low-Beta Stocks to Take Refuge in a Volatile Market Zacks
Aug-02-18 11:47AM  Conatus' (CNAT) Q2 Loss Narrows, Revenues Lag Marginally Zacks +5.08%
08:20AM  Zacks.com featured highlights include: Vanda, Turtle Beach, PCM and Turning Point Zacks
Aug-01-18 05:50PM  Vanda Pharmaceuticals (VNDA) Beats Q2 Earnings Estimates Zacks
04:42PM  Vanda: 2Q Earnings Snapshot Associated Press
04:01PM  Vanda Pharmaceuticals Reports Second Quarter 2018 Financial Results PR Newswire
10:09AM  Endocyte (ECYT) Posts Narrower-Than-Expected Loss in Q2 Zacks
Jul-26-18 09:59AM  The Zacks Analyst Blog Highlights: Illumina, Ultragenyx Pharmaceutical, Xenon Pharmaceuticals, Vanda Pharmaceuticals and Pharming Group Zacks
Jul-25-18 12:24PM  AbbVie Secures FDA Approval for Endometriosis Drug Elagolix Zacks
07:58AM  Bet on These 5 Biotech Stocks as Trump Raises Trade Tensions Zacks
Jul-24-18 12:00PM  AstraZeneca Sells Atacand's European Rights to Cheplapharm Zacks
Vanda Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system disorders. The company's marketed products include HETLIOZ (tasimelteon), a product for the treatment of non-24-hour sleep-wake disorders; and Fanapt (iloperidone), a product for the treatment of schizophrenia. Its products also include Tradipitant (VLY-686), a small molecule neurokinin-1 receptor antagonist that is under the clinical development for the treatment of chronic pruritus in atopic dermatitis and gastroparesis; VTR-297, a small molecule histone deacetylase inhibitor, which is in development for the treatment of hematologic malignancies; and VQW-765, a Phase II alpha-7 nicotinic acetylcholine receptor partial agonist. In addition, the company is developing cystic fibrosis transmembrane conductance regulator activators and inhibitors. It markets its products in the United States, Canada, Europe, Israel, and Mexico. Vanda Pharmaceuticals Inc. was incorporated in 2002 and is headquartered in Washington, the District of Columbia.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Kelly James PatrickEVP & Chief Financial OfficerJan 03Sale26.091,61942,232193,473Jan 04 04:33 PM
Polymeropoulos Mihael HristosPresident and CEOJan 03Sale26.044,447115,8041,163,636Jan 04 04:31 PM
Birznieks GuntherSVP, Business DevelopmentJan 03Sale26.091,61942,232133,780Jan 04 04:34 PM
Birznieks GuntherSVP, Business DevelopmentJan 02Sale26.474,442117,578135,399Jan 04 04:34 PM
Reverberi Gian PieroSVP & Chief Commercial OfficerJan 02Sale26.591,13030,042138,870Jan 04 04:37 PM
Kelly James PatrickEVP & Chief Financial OfficerJan 02Sale26.474,442117,579195,092Jan 04 04:33 PM
Polymeropoulos Mihael HristosPresident and CEOJan 02Sale26.5010,789285,8581,168,083Jan 04 04:31 PM
Watkins ThomasDirectorMay 03Option Exercise4.9815,00074,70020,000May 04 04:06 PM
DUGAN RICHARD WDirectorMar 19Option Exercise4.9815,00074,70025,770Mar 20 05:02 PM
Polymeropoulos Mihael HristosPresident and CEOMar 01Sale18.7260,9661,141,0031,182,872Mar 02 05:36 PM
Birznieks GuntherSVP, Business DevelopmentMar 01Sale18.728,525159,605139,841Mar 02 05:32 PM
Kelly James PatrickEVP & Chief Financial OfficerMar 01Sale18.728,532159,712199,534Mar 02 05:34 PM
Gulino Richard L.SVP, General Counsel & Sec.Mar 01Sale18.713,66068,473115,073Mar 02 05:33 PM
open in yahoo | open in reuters | open in google